B+
Bull case
25%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
GLUE
Monte Rosa TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
GFORCE-1 showed substantial NEK7 degradation, biomarker reductions and no reported serious adverse events over four weeks of dosing. Successful Phase 2 execution across several indications, alongside a favorable MRT-2359 update, could expand the pipeline's value.
Posture
Mixed
Lead driver
Sentiment
What changed
1 setup hits (3d) with net bullish as of 2026-10-26.
What can break
GFORCE-1 measured short-term target engagement, biomarkers and safety, not reduced cardiovascular events or durable clinical benefit. [#8-K-2026-10-01]
Momentum
8
Value
41
Sentiment
73
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $12.00 · Bull $19.00 · Bear $6.00Analysis 2026-10-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $26.88
Why
Momentum8 · Δ7d +3.7
Value41 · Δ7d -0.0
Sentiment73 · Δ7d -14.2
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Confirming evidence
- • 1 setup hits (3d) with net bullish as of 2026-10-26.
- • Sentiment remains the lead driver in the composite, 7D delta -14.2.
Contradictions & invalidation
- • GFORCE-1 measured short-term target engagement, biomarkers and safety, not reduced cardiovascular events or durable clinical benefit. [#8-K-2026-10-01]
- • GFORCE-2 timing has slipped; its six-month design awaits regulatory feedback and long-term toxicology support. [#8-K-2026-10-01] [#SEC-8K-2026-08-06]
- • The coronary-disease Phase 2b start moved from an H2 2026 expectation to H1 2027 and still depends on regulatory feedback and long-term toxicology support.
Catalyst clock
2026-12-31
MRT-2359 prostate-cancer data update
Lead driver: Sentiment · See AI snapshot
Momentum
8
8% active weight
Current posture
7d trendFlat
Δ7d
+3.7
Δ21d
+4.0
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
73
45% active weight
Current posture
7d trendSoftening
Δ7d
-14.2
Δ21d
-46.8
Why this grade
Composite grade C. Momentum 7.8 / Value 40.6 / Sentiment 72.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-25. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$894.08M
Beta
1.61
Shares Out
85.31M
P/E (TTM)
57.5
P/S (TTM)
5.17
P/FCF (TTM)
6.47
Rev YoY
-61.3%
EPS YoY
+185.8%
Gross Margin
+71.7%
Op Margin
-633.0%
Net Debt
-$337.91M
Current Ratio
10.58
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data